Welcome to our dedicated page for INTENSITY THERAPEUTICS SEC filings (Ticker: INTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intensity Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing intratumoral cancer therapies led by INT230-6. Form 8-K reports furnish operating results, financial-condition updates, investor-presentation materials, and clinical-development summaries tied to the company’s non-covalent drug-conjugation platform and oncology studies.
The filing record also covers capital-structure and public-company matters, including an at-the-market common stock offering program, amendments related to a reverse stock split, Nasdaq minimum-bid-price compliance, and modifications to security-holder rights. Proxy materials describe annual meeting proposals, board elections, independent auditor ratification, and amendments to equity compensation and employee stock purchase plans.
Intensity Therapeutics has filed an S-8 registration statement to register additional shares under its employee benefit plans. The registration covers:
- 529,300 additional shares of common stock under the 2021 Stock Incentive Plan (adding to 4,196,606 previously registered shares)
- 500,000 new shares under the 2024 Employee Stock Purchase Plan
The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The filing incorporates by reference several documents including the company's 2024 Annual Report, Q1 2025 Quarterly Report, and recent Current Reports. The registration includes standard indemnification provisions for directors and officers under Delaware law, backed by D&O insurance coverage.